Logotype for Poseida Therapeutics Inc

Poseida Therapeutics (PSTX) investor relations material

Poseida Therapeutics Stifel 2024 Healthcare Conference summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Poseida Therapeutics Inc
Stifel 2024 Healthcare Conference summary18 Nov, 2024

Key business highlights

  • Poseida Therapeutics leverages a proprietary genetic engineering toolkit for both allogeneic CAR T therapies and in vivo genetic medicines, supported by major partnerships with Roche (heme malignancies) and Astellas (solid tumors).

  • The company’s non-viral transposon technology and CasClover gene editor offer high-fidelity gene editing and efficient gene insertion, enabling single-step processes and lower production costs.

  • In-house GMP manufacturing yields over 100 doses per donor batch, reducing labor and operating costs, and supports all clinical-stage programs.

  • Over $400 million in partnership payments and milestones have been collected in the past three years, validating the business model and funding operations.

  • The company is well-capitalized into early 2026, with additional potential milestone payments anticipated.

Pipeline and clinical progress

  • Lead program PBCMA ALLO-1 for multiple myeloma (partnered with Roche) is in Phase 1b, showing rapid patient treatment and high response rates (91% in arm C), including in high-risk and previously treated populations.

  • Additional programs include PCD19, CD20 ALLO-1 (B cell malignancies), a wholly owned PBCMA CD19 ALLO-1 (for myeloma, lymphoma, autoimmune), and MUC1C (solid tumors), with several INDs planned for 2025.

  • Genetic medicine pipeline features non-viral gene editing for hereditary angioedema (PKLKB 101) and gene insertion for hemophilia A (P-Factor VIII101), both in preclinical stages.

  • Early data from the hemophilia A program show stable, long-term factor VIII production in animal models, addressing durability challenges seen in other gene therapies.

  • The company plans further clinical data updates in 2024 and 2025, including for MUC1C and PCD19, CD20 programs.

Technology differentiation and strategy

  • Poseida’s allogeneic CAR T products are based on T stem cell memory cells, engineered using non-viral transposon technology for superior safety and efficacy.

  • The CasClover editor enables high-fidelity, single-step gene editing and insertion in resting T cells, preserving desired cell phenotypes.

  • Embedded safety switches and scalable manufacturing support outpatient and community-based treatment, with no need for apheresis or bridging therapy.

  • The BCMA/CD19 dual-targeting approach offers comprehensive B cell depletion, with potential applications in autoimmune diseases and hematologic malignancies.

  • The company’s platform is positioned for rapid expansion into autoimmune indications, with INDs for new assets expected in 2025.

Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Your earnings 
season toolkit.
Download
Free on both iOS & Android.

The essential earnings season companion

The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

Live calls and transcripts

Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.

Find what you need faster

Search for any keyword across all transcripts simultaneously.

Easily store key findings

Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Your watchlist. Your dashboard.

Follow the companies that matter to you. Get a personalized feed with real-time updates.

Be the first to know

Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.

Consensus estimates

Access analyst consensus estimates, valuation multiples, and revenue segments splits.

All IR material in one place

The easiest way to stay updated during earnings season.

Global coverage

All events from public companies. Live and recorded.

Just click and listen

No webcast links. No manual registrations.

Research anytime, anywhere

Built for professionals. Loved by everyone. Try our free mobile app.

excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com

Frequently asked questions

Poseida Therapeutics, Inc. (PSTX) is a clinical-stage biopharmaceutical company that specializes in developing innovative cell and gene therapies. These therapies aim to provide cures for cancers and genetic diseases by leveraging non-viral gene engineering technologies. Poseida's product pipeline includes both autologous and allogeneic chimeric antigen receptor T cell (CAR-T) therapies, which are at the forefront of treating hematological malignancies and solid tumors. The company is headquartered in San Diego, California, and its shares are listed on the NASDAQ.

Quartr provides global coverage of all investor relation material from public companies.

  • Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

  • Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.

  • Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.

Yes, the Quartr mobile app is free on both iOS and Android.

Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.

Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.

Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.

Explore our global coverage